BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

Atara follows Phase I MS data with $178M offering  Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $175.5 million in a follow-on a day after reporting Phase I data ATA188 reduced disability in multiple sclerosis patients. The company’s...
BioCentury | May 26, 2020
Product Development

Understanding and weaponizing immune responses to COVID-19

Human B and T cell responses to the novel coronavirus provide natural biomarkers and blueprints for COVID-19 countermeasures. Virtual presentations hosted Thursday by BioCentury and Repertoire Immune Medicines Inc. showcased emerging work on SARS-CoV-2 antigens...
BioCentury | Apr 23, 2020
Product Development

BioCentury expands COVID-19 gateway to connect biotechs, researchers with COVID R&D consortium members

BioCentury has expanded the reach of its COVID-19 Resource Center to enable companies and researchers to submit details of investigational products directly to the pharma companies collaborating within the COVID R&D consortium. The consortium, comprising...
BioCentury | Apr 18, 2020
Product Development

Collaborating to clobber COVID-19

An overlapping set of collaborations is focusing the combined intellectual, logistic and economic resources of the life sciences industry, government, academia and non-profits against SARS-Cov2, the virus that causes COVID-19. The latest and broadest collaboration...
BioCentury | Apr 16, 2020
Deals

COVID R&D: Pharmas align behind crowdsourcing solution

Within under a month, a group that started as a mash-up of research heads has morphed into an organized and streamlined collaboration among top pharmaceutical company R&D leaders. Its simple name: COVID R&D. Its goal:...
BC Extra | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the technology is starting to deliver on its first promise to drug developers: speeding up the chemistry they already...
BC Innovations | Nov 22, 2019
Emerging Company Profile

Longwood launches Immunitas with $39M and single-cell genomics platform

With $39M series A, Immunitas is harnessing single-cell analysis to identify new immune targets for cancer. Immunitas Therapeutics emerged from stealth mode on Thursday with a $39 million series A round and a single-cell genomics...
BC Extra | Oct 11, 2019
Company News

Oct. 11 Company Quick Takes: FDA approves Lilly migraine drug; plus Clovis, Evotec-Celmatix, Avacta-ADC and Neumentum-J&J

FDA approves Lilly’s Reyvow for migraine   FDA approved Reyvow lasmiditan from Eli Lilly and Co. (NYSE:LLY) to treat acute migraine with or without aura. It is the first agonist of serotonin (5-HT1F) approved for...
BioCentury | Oct 4, 2019
Finance

Selectivity sets off $37M series A for mTOR company Aeovian

Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s $37 million series A after long eyeing the space. “mTORC1 selective inhibition has been a Holy Grail target in...
BC Extra | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

FDA approves Bavarian Nordic’s smallpox/monkeypox vaccine  FDA approved Jynneos MVA-BN from Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) to prevent smallpox and monkeypox, making the vaccine the only approved non-replicating smallpox vaccine in the U.S. and the...
Items per page:
1 - 10 of 856
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

Atara follows Phase I MS data with $178M offering  Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $175.5 million in a follow-on a day after reporting Phase I data ATA188 reduced disability in multiple sclerosis patients. The company’s...
BioCentury | May 26, 2020
Product Development

Understanding and weaponizing immune responses to COVID-19

Human B and T cell responses to the novel coronavirus provide natural biomarkers and blueprints for COVID-19 countermeasures. Virtual presentations hosted Thursday by BioCentury and Repertoire Immune Medicines Inc. showcased emerging work on SARS-CoV-2 antigens...
BioCentury | Apr 23, 2020
Product Development

BioCentury expands COVID-19 gateway to connect biotechs, researchers with COVID R&D consortium members

BioCentury has expanded the reach of its COVID-19 Resource Center to enable companies and researchers to submit details of investigational products directly to the pharma companies collaborating within the COVID R&D consortium. The consortium, comprising...
BioCentury | Apr 18, 2020
Product Development

Collaborating to clobber COVID-19

An overlapping set of collaborations is focusing the combined intellectual, logistic and economic resources of the life sciences industry, government, academia and non-profits against SARS-Cov2, the virus that causes COVID-19. The latest and broadest collaboration...
BioCentury | Apr 16, 2020
Deals

COVID R&D: Pharmas align behind crowdsourcing solution

Within under a month, a group that started as a mash-up of research heads has morphed into an organized and streamlined collaboration among top pharmaceutical company R&D leaders. Its simple name: COVID R&D. Its goal:...
BC Extra | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the technology is starting to deliver on its first promise to drug developers: speeding up the chemistry they already...
BC Innovations | Nov 22, 2019
Emerging Company Profile

Longwood launches Immunitas with $39M and single-cell genomics platform

With $39M series A, Immunitas is harnessing single-cell analysis to identify new immune targets for cancer. Immunitas Therapeutics emerged from stealth mode on Thursday with a $39 million series A round and a single-cell genomics...
BC Extra | Oct 11, 2019
Company News

Oct. 11 Company Quick Takes: FDA approves Lilly migraine drug; plus Clovis, Evotec-Celmatix, Avacta-ADC and Neumentum-J&J

FDA approves Lilly’s Reyvow for migraine   FDA approved Reyvow lasmiditan from Eli Lilly and Co. (NYSE:LLY) to treat acute migraine with or without aura. It is the first agonist of serotonin (5-HT1F) approved for...
BioCentury | Oct 4, 2019
Finance

Selectivity sets off $37M series A for mTOR company Aeovian

Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s $37 million series A after long eyeing the space. “mTORC1 selective inhibition has been a Holy Grail target in...
BC Extra | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

FDA approves Bavarian Nordic’s smallpox/monkeypox vaccine  FDA approved Jynneos MVA-BN from Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) to prevent smallpox and monkeypox, making the vaccine the only approved non-replicating smallpox vaccine in the U.S. and the...
Items per page:
1 - 10 of 856